Abstract
The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1165-1170 |
| Number of pages | 6 |
| Journal | American Journal of Diseases of Children |
| Volume | 145 |
| Issue number | 10 |
| State | Published - 1991 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Growth hormone therapy in hypophosphatemic rickets. / Wilson, D. M.; Lee, Phillip; Morris, A. H.; Reiter, E. O.; Gertner, J. M.; Marcus, R.; Quarmby, V. E.; Rosenfeld, R. G.
In: American Journal of Diseases of Children, Vol. 145, No. 10, 1991, p. 1165-1170.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Growth hormone therapy in hypophosphatemic rickets
AU - Wilson, D. M.
AU - Lee, Phillip
AU - Morris, A. H.
AU - Reiter, E. O.
AU - Gertner, J. M.
AU - Marcus, R.
AU - Quarmby, V. E.
AU - Rosenfeld, R. G.
PY - 1991
Y1 - 1991
N2 - The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.
AB - The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 ± 0.13 mmol/L (mean ± SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 ± 0.08 mmol/L to 0.83 ± 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.
UR - http://www.scopus.com/inward/record.url?scp=0025939791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025939791&partnerID=8YFLogxK
M3 - Article
C2 - 1928011
AN - SCOPUS:0025939791
VL - 145
SP - 1165
EP - 1170
JO - JAMA Pediatrics
JF - JAMA Pediatrics
SN - 2168-6203
IS - 10
ER -